Biotech News
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
investor.assemblybio.com2026-05-07 20:02 EST
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH